68Ga-DOTATOC
Authors:
Michal Budinský; Petr Vyšinský; Stanislav Synek; Beatrix Bencsiková; Iveta Selingerová; Zdeněk Řehák
Published in:
Čes. slov. Farm., 2021; 70, 136-141
Category:
Original Article
doi:
https://doi.org/https://doi.org/10.5817/CSF2021-4-136
Overview
The radiopharmaceutical 68Ga-DOTATOC represents the latest radiopharmaceutical in the diagnosis of a neuroendocrine tumor with somatostatin receptor overexpression. Technological and economic difficulties of preparing and quality control of the radiopharmaceutical limit its use to specialised departments. Background of the department with rich experience with radiopharmaceuticals for positron emission tomography allows handling more difficult 68Ga-radiopharmacy and may increase and improve the care of oncology patients.
Keywords:
68Ga-DOTATOC – radiopharmacy – neuroendocrine tumors
Sources
1. Patel Y. C. Somatostatin and its receptor family. Frontiers in Neuroendocrinology 1999; 20(3), 157–198.
2. Patel Y. C., Strikant C. B. Somatostatin receptors. Trends Endocrinol Metab. 1997; 8(10), 398–405.
3. Papotti M., Bongiovanni M., Volante M., Allia E., Landolfi S., Helboe L., Schindler M., Cole S. L., Bussolati G. Expression of somatostatin receptor types 1–5 in 81 cases of gastrointestinal and pancreatic endocrine tumors: a correlative immunohistochemical and reverse- transcriptase polymerase chain reaction analysis. Virchows arch. 2002; 440(5), 461–175.
4. Vítek P. Neuroendokrinní nádory, in Onkologie v klinické praxi. Standardní přístupy v diagnostice a léčbě vybraných zhoubných nádorů. Praha: Mladá fronta 2019.
5. Sedláčková E., Bajčiová V., a kol. Epidemiologie NEN ve světe a v ČR, registry. In: Neuroendokrinní nádory. Praha: Maxdorf 2016.
6. Wang L., Tang K., Zhang Q., Li H., Wen Z., Zhang H. Somatostatin Receptor-Based MoleculaImaging and Therapy for Neuroendocrine Tumors. Biomed Res Int. 2013; 2013, 102819.
7. Pauwels E., Cleeren F., Bormans G., Deroose C. M. Somatostatin receptor PET ligands – the next generation for clinical practice. Am. J. Nucl. Med. Mol. Imag. 2018; 8(5), 311–331.
8. Gabriel M., Decristoforo C., Kendler D., Dobrozemsky G., Heute D., Uprimny C., Kovacs P., Guggenberg E., Bale R., Virgolini I. J. 68Ga-DOTA-Tyr3-Octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J. Nucl. Med. 2007; 48, 508–518.
9. Bencsiková B., Řehák Z., Budinský M., Hejnová R., Kozáková Š., Kiss I., Demlova R., Svoboda M. 68Ga- DOTA-TOC PET/CT vyšetření u pacienta s gastroenteropankreatickým neuroendokrinním nádorem – první vyšetření v České republice. Klin. Onkol. 2019; 32(5), 390–392.
10. Monaharan P., Lamarca A., Navalkissoor S., Calero J., Chan P. S, Julyan P., Sierra M., Caplin M., Valle J. Safety, tolerability and clinical implementation of „ready-to-use“ 68gallium-DOTA0-Tyr3-octreotide (68Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastropancreatic neuroendocrine tumors (GEP-NETs). ESMO Open. 2020; 5, e000650.
11. Calero J. Kits or synthesis modules? A review of both strategies. Ga-68 for beginners. London: UKRG 2018.
12. Murby B. Radiation risk assessment. Ga-68 for beginners. London: UKRG 2018.
Labels
Pharmacy Clinical pharmacologyArticle was published in
Czech and Slovak Pharmacy
2021 Issue 4
Most read in this issue
- 68Ga-DOTATOC
- The role of vitamin D in primary and secondary prevention in orthopaedic patients
- Specific nature of medicines and value of medicines
- Pharmaceutical Art and Peculiarities in the Latin Dissertation De phthisi (On Tuberculosis) from 1679 by Slovak Physician Matúš Palumbini